Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Renalytix ( (GB:RENX) ).
Renalytix announced that its kidneyintelX.dkd test has been featured in the Journal of the American Society of Nephrology, highlighting its significance in precision medicine for diabetic kidney disease. The test’s inclusion in the KDIGO guidelines and its role in facilitating personalized care underscores its potential to transform treatment paradigms, especially with new drug approvals like Ozempic for DKD, by providing risk-based treatment pathways that enhance patient outcomes while controlling healthcare costs.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing the clinical management of kidney disease to improve patient outcomes. The company has received FDA approval and Medicare reimbursement for its product, kidneyintelX.dkd, which supports early-stage risk assessment for chronic kidney disease and is commercially available in the United States.
YTD Price Performance: 103.75%
Average Trading Volume: 1,400
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.37M
For detailed information about RENX stock, go to TipRanks’ Stock Analysis page.
